Insiders · CTKB

Jack Ball

Director at Cytek Biosciences, Inc. (CTKB)

Jack Ball has filed 8 insider reports with the SEC since June 2022, as director at Cytek Biosciences, Inc. (CTKB). Jack Ball made no open-market purchases or sales in the last 12 months. The latest filing, on June 12, 2026, reports exercise or conversion of a derivative at Cytek Biosciences, Inc. (CTKB).

Filings
8
Companies
1
Bought on market
None
Sold on market
$235K

Companies where Jack Ball is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Cytek Biosciences, Inc. logo
CTKB
Cytek Biosciences, Inc.
Director86,678$235K$6.12Jun 12, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Jack Ball with

Other insiders at the same companies

Questions about Jack Ball

What is Jack Ball's role at Cytek Biosciences, Inc.?
Jack Ball reports to the SEC as director at Cytek Biosciences, Inc. (CTKB), according to the latest filing on June 12, 2026.
How many shares does Jack Ball own?
After the latest filing that states it, Jack Ball directly owned 86,678 shares of Cytek Biosciences, Inc. (CTKB). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Jack Ball bought or sold stock recently?
The most recent open-market sale was on November 14, 2022: sold 16,000 shares of Cytek Biosciences, Inc. (CTKB) for $235K at an average of $14.69.
How do I get alerts when Jack Ball files?
Follow Jack Ball on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Jack Ball (SEC CIK 0001873083). Totals count each trade once, skipping amendments whose original is on file, from Jun 3, 2022 on. View on SEC EDGAR · Get this as JSON